These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 16411132)
1. CD56 expression aids in the differential diagnosis of cholangiocarcinomas and benign cholangiocellular lesions. Gütgemann I; Haas S; Berg JP; Zhou H; Büttner R; Fischer HP Virchows Arch; 2006 Apr; 448(4):407-11. PubMed ID: 16411132 [TBL] [Abstract][Full Text] [Related]
2. Novel immunohistochemical markers differentiate intrahepatic cholangiocarcinoma from benign bile duct lesions. Bertram S; Padden J; Kälsch J; Ahrens M; Pott L; Canbay A; Weber F; Fingas C; Hoffmann AC; Vietor A; Schlaak JF; Eisenacher M; Reis H; Sitek B; Baba HA J Clin Pathol; 2016 Jul; 69(7):619-26. PubMed ID: 26729014 [TBL] [Abstract][Full Text] [Related]
3. Intrahepatic clear cell cholangiocarcinoma: immunohistochemical aspects in a very rare type of cholangiocarcinoma. Haas S; Gütgemann I; Wolff M; Fischer HP Am J Surg Pathol; 2007 Jun; 31(6):902-6. PubMed ID: 17527078 [TBL] [Abstract][Full Text] [Related]
4. Cell adhesion molecules P-cadherin and CD24 are markers for carcinoma and dysplasia in the biliary tract. Riener MO; Vogetseder A; Pestalozzi BC; Clavien PA; Probst-Hensch N; Kristiansen G; Jochum W Hum Pathol; 2010 Nov; 41(11):1558-65. PubMed ID: 20621328 [TBL] [Abstract][Full Text] [Related]
5. An immunohistochemical profile of the so-called bile duct adenoma: clues to pathogenesis. Hughes NR; Goodman ZD; Bhathal PS Am J Surg Pathol; 2010 Sep; 34(9):1312-8. PubMed ID: 20679879 [TBL] [Abstract][Full Text] [Related]
6. Cholangiocarcinomas arising in cirrhosis and combined hepatocellular-cholangiocellular carcinomas share apomucin profiles. Sasaki M; Nakanuma Y; Ho SB; Kim YS Am J Clin Pathol; 1998 Mar; 109(3):302-8. PubMed ID: 9495202 [TBL] [Abstract][Full Text] [Related]
7. S100P immunostaining identifies a subset of peripheral-type intrahepatic cholangiocarcinomas with morphological and molecular features similar to those of perihilar and extrahepatic cholangiocarcinomas. Tsai JH; Huang WC; Kuo KT; Yuan RH; Chen YL; Jeng YM Histopathology; 2012 Dec; 61(6):1106-16. PubMed ID: 22882148 [TBL] [Abstract][Full Text] [Related]
8. Biliary carcinoembryonic antigen levels are a marker for cholangiocarcinoma. Nakeeb A; Lipsett PA; Lillemoe KD; Fox-Talbot MK; Coleman J; Cameron JL; Pitt HA Am J Surg; 1996 Jan; 171(1):147-52; discussion 152-3. PubMed ID: 8554130 [TBL] [Abstract][Full Text] [Related]
9. Bile duct adenoma may be a precursor lesion of small duct type intrahepatic cholangiocarcinoma. Sasaki M; Sato Y; Nakanuma Y Histopathology; 2021 Jan; 78(2):310-320. PubMed ID: 33405289 [TBL] [Abstract][Full Text] [Related]
10. Hilar bile duct cancer associated with preoperatively undetectable von Meyenburg complex--report of a case. Eguchi S; Tajima Y; Yanaga K; Okudaira S; Furui J; Hayashi T; Kanematsu T Hepatogastroenterology; 2004; 51(59):1301-3. PubMed ID: 15362738 [TBL] [Abstract][Full Text] [Related]
11. The expression of matrix metalloproteinases in intrahepatic cholangiocarcinoma, hilar (Klatskin tumor), middle and distal extrahepatic cholangiocarcinoma, gallbladder cancer, and ampullary carcinoma: role of matrix metalloproteinases in tumor progression and prognosis. Kirimlioğlu H; Türkmen I; Başsüllü N; Dirican A; Karadağ N; Kirimlioğlu V Turk J Gastroenterol; 2009 Mar; 20(1):41-7. PubMed ID: 19330734 [TBL] [Abstract][Full Text] [Related]
12. Diagnostic utility of CD10 in benign and malignant extrahepatic bile duct lesions. Tretiakova M; Antic T; Westerhoff M; Mueller J; Himmelfarb EA; Wang HL; Xiao SY Am J Surg Pathol; 2012 Jan; 36(1):101-8. PubMed ID: 21989348 [TBL] [Abstract][Full Text] [Related]
13. Regulators of apoptosis in cholangiocarcinoma. Jhala NC; Vickers SM; Argani P; McDonald JM Arch Pathol Lab Med; 2005 Apr; 129(4):481-6. PubMed ID: 15794670 [TBL] [Abstract][Full Text] [Related]
14. N-cadherin serves as diagnostic biomarker in intrahepatic and perihilar cholangiocarcinomas. Mosnier JF; Kandel C; Cazals-Hatem D; Bou-Hanna C; Gournay J; Jarry A; Laboisse CL Mod Pathol; 2009 Feb; 22(2):182-90. PubMed ID: 18622386 [TBL] [Abstract][Full Text] [Related]
15. Role of CD56-expressing immature biliary epithelial cells in biliary atresia. Zhang RZ; Yu JK; Peng J; Wang FH; Liu HY; Lui VC; Nicholls JM; Tam PK; Lamb JR; Chen Y; Xia HM World J Gastroenterol; 2016 Feb; 22(8):2545-57. PubMed ID: 26937142 [TBL] [Abstract][Full Text] [Related]
16. A subgroup of intrahepatic cholangiocarcinoma with an infiltrating replacement growth pattern and a resemblance to reactive proliferating bile ductules: 'bile ductular carcinoma'. Kozaka K; Sasaki M; Fujii T; Harada K; Zen Y; Sato Y; Sawada S; Minato H; Matsui O; Nakanuma Y Histopathology; 2007 Sep; 51(3):390-400. PubMed ID: 17553067 [TBL] [Abstract][Full Text] [Related]
18. NEU overexpression in the furan rat model of cholangiocarcinogenesis compared with biliary ductal cell hyperplasia. Sirica AE; Radaeva S; Caran N Am J Pathol; 1997 Dec; 151(6):1685-94. PubMed ID: 9403719 [TBL] [Abstract][Full Text] [Related]
19. [Gallbladder and bile duct carcinoma. Biology and pathology]. Tannapfel A; Wittekind C Internist (Berl); 2004 Jan; 45(1):33-41. PubMed ID: 14735242 [TBL] [Abstract][Full Text] [Related]
20. Dyskerin expression in human fetal, adult and neoplastic intrahepatic bile ducts: correlations with cholangiocarcinoma aggressiveness. Vasuri F; Rocchi L; Degiovanni A; Giunchi F; Brandi G; Treré D; Montanaro L; D'Errico-Grigioni A Histopathology; 2015 Jan; 66(2):244-51. PubMed ID: 25367684 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]